<DOC>
	<DOCNO>NCT02855580</DOCNO>
	<brief_summary>The purpose study examine feasibility , acceptability , utility pharmacogenomic ( PGX ) testing ( specifically cytochrome P450 2D6 2C19 gene ) prior initiate treatment antidepressant ( AD ) among child adolescent University Florida Child Psychiatry clinic .</brief_summary>
	<brief_title>Integrating Pharmacogenomic Testing Into Child Psychiatry Clinic</brief_title>
	<detailed_description>This project assess feasibility implement pharmacogenomic testing ( PGX ) specific gene involve metabolism antidepressant ( CYP2D6 CYP2C19 ) child psychiatry clinic UF . Although widely implement date , naturalistic study adult psychiatry population show PGX test improve patient outcome , increase medication adherence , reduce cost . However , study psychiatry-focused PGX test child . One every four child adolescents suffers mental illness ( half mood anxiety disorder ) severe enough impact function school , home , important area . Although psychotherapy remain first line treatment child mild uncomplicated symptom , use psychotropic medication child increase steadily last decade . These medication effective many child , carry substantial risk side effect , include gastrointestinal , cognitive , systemic , psychiatric ( include treatment emergent suicidal ideation ) . For treatment responder , improvement typically see four eight week target dose achieve ( twelve week obsessive compulsive disorder ) . Thus , identify best medication option prior treatment initiation could decrease likelihood side effect severe enough require medication discontinuation change , minimize time response . In study , 50 child adolescent major depression , anxiety , obsessive compulsive disorder begin treatment new antidepressant recruit PGX test conduct . Twenty five child randomize receive PGX test prior starting/changing medication 25 receive treatment usual ( child receive PGX result end 12 week ) . Members UF Health Personalized Medicine Program provide education prescribing clinician PGX test create patient-specific consultation regard PGX result . Assess clinician ' parent ' willingness use PGX test make treatment decision , well knowledge belief PGX test ( pre-and post-study ) . Also assess , pilot data large randomize control trial , difference side effect profile , treatment adherence , symptom improvement PGX case control .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Male female age 8 20 year old Have diagnose receive treatment mood disorder , anxiety , obsessive compulsive disorder Receiving treatment UF child psychiatry clinic Children primary diagnosis autism High risk suicide Children determine UF psychiatrist ill tolerate wait two week begin medication treatment</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pharmacogenomic</keyword>
	<keyword>child</keyword>
	<keyword>psychiatry</keyword>
	<keyword>Obsessive Compulsive Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Anxiety</keyword>
	<keyword>CYP2D6</keyword>
	<keyword>CYP2C19</keyword>
	<keyword>Selective serotonin reuptake inhibitor</keyword>
	<keyword>SSRI</keyword>
</DOC>